Pennsylvania is currently home to 3460 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
Recruiting
The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) .
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
12/21/2022
Locations: Rothman, Philadelphia, Pennsylvania
Conditions: Joint Infection
Inspiring New Science In Guiding Healthcare in Turner Syndrome Registry
Recruiting
INSIGHTS is a registry research study that collects key information on medical history for girls and women with Turner syndrome and the clinical care they receive. This includes genetic tests, imaging, medications, and more for hundreds of patients seen at a number of clinics across the US. In addition to learning a lot about the current state of health for individuals with TS, INSIGHTS serves as an infrastructure to conduct future studies are meaningful to patients and their families.
Gender:
Female
Ages:
All
Trial Updated:
12/19/2022
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Turner Syndrome
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Recruiting
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/16/2022
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Solid Tumor
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Recruiting
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/15/2022
Locations: Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Lung Cancer, Non-Small-Cell, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury
Recruiting
A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries. 150 male and female participants aged 6-16 and 18-45 with soft tissue injuries meeting the following criteria will be enrolled to evaluate the pharmacokinetics and safety of the Licart topical system in pediatric and adult participants with minor soft tissue injuries over a 14-day treatment course. The ana... Read More
Gender:
All
Ages:
Between 6 years and 45 years
Trial Updated:
12/12/2022
Locations: Center for Orthopaedics and Sports Medicine, Indiana, Pennsylvania
Conditions: Soft Tissue Injuries
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy
Gender:
All
Ages:
18 years and above
Trial Updated:
12/09/2022
Locations: GSK Investigational Site, Bethlehem, Pennsylvania
Conditions: Neoplasms
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
Recruiting
Phase 1: The objective of the Phase 1 part of the clinical trial is to verify safety and tolerability (dose-limiting toxicity [DLT], maximum tolerated dose [MTD]) of a single 3.7 Giga-Becquerel (GBq) dose with the potential for one dose level de-escalation to 2.775 GBq if necessary, to determine the recommended [177Lu]Ludotadipep dose for use in the Phase 2a part of the trial. Phase 2a: The objective of the Phase 2a part of the trial is to evaluate safety and efficacy for repeated administratio... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
12/08/2022
Locations: Pennsylvania Cancer Specialists & Research Institute (Formerly Gettysburg Cancer Center), Gettysburg, Pennsylvania
Conditions: Metastatic Castration-resistant Prostate Cancer
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
Recruiting
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
12/06/2022
Locations: Frontier Clinical Research, LLC, Smithfield, Pennsylvania
Conditions: COVID-19
Knee Related Subchondral Bone Lesions Treated With IOBP
Recruiting
The study will be a prospective, multicenter clinical study evaluating clinical and patient reported outcome measures of subjects receiving IOBP® surgical technique using Angel cPRP and BMA processing system to treat subchondral bone pathology (SBP).
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
12/02/2022
Locations: Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania
Conditions: Subchondral Cyst
Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures
Recruiting
The purpose of this investigation is to compare functional outcome measures and range of motion for patients receiving glucocorticoid (GC) injections versus those not receiving GCs for the treatment of distal radius fractures. The investigators hypothesize that patients who receive GC will have improved ROM and functional outcome measures compared to patients who do not receive GC. In addition, this study aims to determine if there is a difference in rates of complications and postoperative pain... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2022
Locations: Geisinger Woodbine, Danville, Pennsylvania
Conditions: Distal Radius Fracture
Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options
Recruiting
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.
Gender:
All
Ages:
16 years and above
Trial Updated:
11/30/2022
Locations: UPMC, Pittsburgh, Pennsylvania
Conditions: Invasive Fungal Infections
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Recruiting
Subjects will be offered the opportunity to participate in a randomized, controlled, 2-arm, unblinded multicenter trial (RCT). There will be 2 study arms: the control arm receiving chemotherapy with the modified FOLFIRINOX regimen alone; and the irreversible electroporation (IRE) arm, receiving chemotherapy with the modified FOLFIRINOX regimen followed by IRE with the NanoKnife System using either an open or a percutaneous approach. All subjects will be treated with the modified FOLFIRINOX regim... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/23/2022
Locations: St. Luke's Cancer Center, Easton, Pennsylvania
Conditions: Stage III Pancreatic Cancer